| Description | Anti-DLL3 antibody binds specifically to human DLL3 protein (hDLL3) EGF2 domain. It was screened from hybridoma and can be developed into a chimeric antibody. The epitope mapping of the antibody was determined through Flow Cytometry. |
| Clonality | Monoclonal |
| Host Species | Mouse |
| Target Species | Human |
| Immunogen | Human DLL3-fc protein (hDLL3-Fc) |
| Epitope | EGF2 domain, aa 274-310 (conformational epitope) |
| Isotype | Mouse IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein G affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | ELISA; FC |
| Application Notes | This antibody is recommended for detection of human DLL3 by ELISA. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Post Translational Modification | Ubiquitinated by MIB (MIB1 or MIB2), leading to its endocytosis and subsequent degradation. |
